Exploratory INDs Will Better Serve Large Companies, PDL Exec Says
Executive Summary
Exploratory investigational new drug applications will provide a greater benefit to large pharma and biotech companies, Protein Design Labs CEO Mark McDade said at the Biotechnology Industry Organization Windhover conference in Washington, D.C. April 26
You may also be interested in...
FDA Stressing Statistical Outcomes Over Standardization In Imaging Trials
FDA is emphasizing statistical outcomes over protocol standardization when assessing imaging studies, according to Division of Medical Imaging Drug Products Director George Mills
FDA Stressing Statistical Outcomes Over Standardization In Imaging Trials
FDA is emphasizing statistical outcomes over protocol standardization when assessing imaging studies, according to Division of Medical Imaging Drug Products Director George Mills
Exploratory IND Concept Needs Expansion, Merck Exec Says
FDA should expand its "Exploratory IND" guidance to make it easier for manufacturers to do pilot studies involving radioactive tracers, Merck Division of Imaging Senior Director David Mozley told a May 5 meeting on "Critical Path" opportunities cosponsored by FDA, the Biotechnology Industry Organization and the Drug Information Association in Bethesda, Md